IL39097A - A pyrazolydinyl-phenylphosphoric acid derivative,its salts and their preparation - Google Patents
A pyrazolydinyl-phenylphosphoric acid derivative,its salts and their preparationInfo
- Publication number
- IL39097A IL39097A IL39097A IL3909772A IL39097A IL 39097 A IL39097 A IL 39097A IL 39097 A IL39097 A IL 39097A IL 3909772 A IL3909772 A IL 3909772A IL 39097 A IL39097 A IL 39097A
- Authority
- IL
- Israel
- Prior art keywords
- phenyl
- butyl
- solution
- acid
- water
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 159000000007 calcium salts Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 159000000000 sodium salts Chemical class 0.000 claims description 12
- 150000007530 organic bases Chemical class 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- RSSDWSPWORHGIE-UHFFFAOYSA-N $l^{1}-phosphanylbenzene Chemical compound [P]C1=CC=CC=C1 RSSDWSPWORHGIE-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- -1 organic acid salts Chemical class 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- NPOJQCVWMSKXDN-UHFFFAOYSA-N Dacthal Chemical compound COC(=O)C1=C(Cl)C(Cl)=C(C(=O)OC)C(Cl)=C1Cl NPOJQCVWMSKXDN-UHFFFAOYSA-N 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000011033 desalting Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000000243 solution Substances 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000292 calcium oxide Substances 0.000 description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 3
- GZPOURWDXKURPK-UHFFFAOYSA-L calcium;phenyl phosphate Chemical compound [Ca+2].[O-]P([O-])(=O)OC1=CC=CC=C1 GZPOURWDXKURPK-UHFFFAOYSA-L 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical group [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 229940080435 lactose 250 mg Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XYMSPSSMUWBDBW-UHFFFAOYSA-N O.O.O.O.O.O.O.O.[Ca] Chemical compound O.O.O.O.O.O.O.O.[Ca] XYMSPSSMUWBDBW-UHFFFAOYSA-N 0.000 description 1
- NXVKMUZXOQFFDP-UHFFFAOYSA-H P(=O)([O-])([O-])[O-].[Ca+2].O.O.O.O.O.O.O.O.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].O.O.O.O.O.O.O.O.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] NXVKMUZXOQFFDP-UHFFFAOYSA-H 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT4987771 | 1971-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL39097A0 IL39097A0 (en) | 1972-05-30 |
| IL39097A true IL39097A (en) | 1974-11-29 |
Family
ID=11271759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL39097A IL39097A (en) | 1971-04-21 | 1972-03-28 | A pyrazolydinyl-phenylphosphoric acid derivative,its salts and their preparation |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3803166A (enExample) |
| AR (1) | AR194361A1 (enExample) |
| AU (1) | AU461688B2 (enExample) |
| BE (1) | BE782495A (enExample) |
| CA (1) | CA985691A (enExample) |
| DE (1) | DE2218606A1 (enExample) |
| DK (1) | DK132893C (enExample) |
| ES (1) | ES401952A1 (enExample) |
| FR (1) | FR2133975B1 (enExample) |
| GB (1) | GB1374641A (enExample) |
| IE (1) | IE36232B1 (enExample) |
| IL (1) | IL39097A (enExample) |
| NL (1) | NL7205244A (enExample) |
| PH (1) | PH9791A (enExample) |
| ZA (1) | ZA722068B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113343A1 (en) * | 2003-10-14 | 2005-05-26 | Pliva - Research And Development Ltd. | Solid-state form of alendronate sodium and preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1814649A1 (de) * | 1968-12-13 | 1970-06-25 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung von 1,2-Diphenyl-3,5-dioxopyrazolidin und dessen Substitutionsprodukten |
-
1972
- 1972-03-24 GB GB1395972A patent/GB1374641A/en not_active Expired
- 1972-03-24 CA CA138,054A patent/CA985691A/en not_active Expired
- 1972-03-27 US US00238554A patent/US3803166A/en not_active Expired - Lifetime
- 1972-03-27 ZA ZA722068A patent/ZA722068B/xx unknown
- 1972-03-28 IE IE405/72A patent/IE36232B1/xx unknown
- 1972-03-28 IL IL39097A patent/IL39097A/en unknown
- 1972-03-28 PH PH13394*A patent/PH9791A/en unknown
- 1972-03-30 AU AU40624/72A patent/AU461688B2/en not_active Expired
- 1972-04-17 DE DE19722218606 patent/DE2218606A1/de active Pending
- 1972-04-18 DK DK189472A patent/DK132893C/da active
- 1972-04-19 NL NL7205244A patent/NL7205244A/xx unknown
- 1972-04-20 FR FR7214037A patent/FR2133975B1/fr not_active Expired
- 1972-04-20 ES ES401952A patent/ES401952A1/es not_active Expired
- 1972-04-21 BE BE782495A patent/BE782495A/xx unknown
- 1972-07-13 AR AR241448A patent/AR194361A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| AR194361A1 (es) | 1973-07-13 |
| CA985691A (en) | 1976-03-16 |
| AU461688B2 (en) | 1975-06-05 |
| BE782495A (fr) | 1972-08-16 |
| DK132893B (da) | 1976-02-23 |
| DK132893C (da) | 1976-07-26 |
| ZA722068B (en) | 1972-12-27 |
| PH9791A (en) | 1976-03-17 |
| IE36232L (en) | 1972-10-21 |
| IL39097A0 (en) | 1972-05-30 |
| ES401952A1 (es) | 1975-10-16 |
| AU4062472A (en) | 1973-10-04 |
| FR2133975A1 (enExample) | 1972-12-01 |
| IE36232B1 (en) | 1976-09-15 |
| US3803166A (en) | 1974-04-09 |
| FR2133975B1 (enExample) | 1975-10-31 |
| DE2218606A1 (de) | 1972-11-09 |
| NL7205244A (enExample) | 1972-10-24 |
| GB1374641A (en) | 1974-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19845405C2 (de) | Arylsubstituierte Propanolaminderivate und deren Verwendung | |
| DE2713272C2 (de) | Derivate der 7-Aminothiazolyl-acetamido-cephalosporansäure, ihre Herstellung und pharmazeutische Zusammensetzungen | |
| EP0027258B1 (de) | Phosphorylmuramylpeptide, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln | |
| EP0025495A1 (de) | Lipophile Muramylpeptide, Verfahren zu deren Herstellung und deren Verwendung | |
| DE2015573B2 (de) | a-AminomethyI-3-(hydroxy-, acyloxy- oder acyloxymethyl)- 4-acyloxybenzylalkohole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE3780276T2 (de) | Angstloesende n-(1-azabicyclo(2.2.2)oct-3-yl)benzamide und -thiobenzamide. | |
| DE2812625A1 (de) | Oximderivate der 3-acetoxymethyl-7- aminothiazolyl-acetamido-cephalosporansaeure, ihre herstellung und pharmazeutische mittel | |
| RU2738844C2 (ru) | Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний | |
| FI65624C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara acylerade etanolaminfosfat | |
| DE2154848A1 (de) | Neue O-Ester von Monosacchariden | |
| Wiley et al. | Erythromycin. XII. 1 The Isolation, properties and partial structure of erythromycin C | |
| Tsuda et al. | The alkaloids of Eupatorium maculatum L. | |
| DE69517191T2 (de) | Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels | |
| EP1117676B1 (de) | Mit gallensäuren verknüpfte propanolaminderivate zur behandlung von lipidstoffwechselstörungen | |
| PT89120B (pt) | Processo para a preparacao de novos derivados flavonoides 2-piperazinil-2-oxo-etileno substituidos | |
| JPH08504830A (ja) | スピロスタニルグリコシド結晶質一水塩 | |
| IL39097A (en) | A pyrazolydinyl-phenylphosphoric acid derivative,its salts and their preparation | |
| US3528986A (en) | Disodium 4,4'-disulphoxydiphenyl-(2-pyridyl)-methane | |
| DE3844415A1 (de) | Neue 3-piperidincarboxaldehydoxim-derivate, deren herstellungsverfahren und deren verwendung als arzneimittel | |
| DE2819898A1 (de) | Neue substituierte phenylessigsaeureamidverbindungen und verfahren zu ihrer herstellung | |
| DE2729165C2 (de) | Phenäthylaminderivate und deren Salze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| US4380536A (en) | Pharmaceutical composition containing para-amino-benzoic acid-N-D-mannoside as an active ingredient | |
| US3117059A (en) | O-benzylphenoxy- | |
| US3118876A (en) | Process for preparing glycoside phosphates | |
| US4126616A (en) | N-propylnorapomorphine diesters |